Drug Monograph

Drug/Drug Class:	**RYANODEX™ (dantrolene sodium) for injection / Skeletal muscle relaxant**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Ryanodex™ is available as lyophilized powder for reconstitution containing 250 mg of dantrolene sodium per single-use vial.
Manufacturer:	Eagle Pharmaceuticals, Inc., Woodcliff Lake, NJ 07677 USA
Indications:	Ryanodex™ is a skeletal muscle relaxant indicated for the prevention and treatment of malignant hyperthermia with concurrent, appropriate supportive measures.
Costs:	$2300.00 per vial of Ryanodex™ Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☐ Appropriate Indications ☒ No PA Required

Prepared By: Abbey Mahaney, Pharm. D. Candidate 2015
Date: October 24, 2014

© 2014 Xerox Heritage, LLC All Rights Reserved.